Secretory IgA and Course of COVID-19 in Patients Receiving a BacteriaBased Immunostimulant Agent in Addition to Background Therapy
Journal Title: Journal of Clinical & Cellular Immunology - Year 2023, Vol 14, Issue 2
Abstract
Background: Mucosal immunity plays a major role not only in the prevention but probably also in the outcome of COVID-19. An enhanced production of secretory Immunoglobulin A (sIgA) might contribute to the activation of the immune response mechanisms. Objective: To assess the levels of sIgA produced by epithelial cells in the nasal and pharyngeal mucosa and those measured in salivary gland secretions and to study the course of COVID-19 following the intranasal or subcutaneous administration of a bacteria-based immuno-stimulant agent. Materials and methods: This study included 69 patients aged between 18 and 60, who had moderate COVID-19 infection. They were divided into two groups: Group 1 (control group) included 39 patients who received only background therapy, and Group 2 was made up of 30 patients who received background therapy in combination with the Immunovac VP4 vaccine, a bacteria-based immuno-stimulant agent, which was given for 11 days starting from the day of admission to hospital. The levels of sIgA were measured by ELISA in nasal epithelial swabs, pharyngeal swabs and salivary gland secretions at baseline and on days 14 and 30. Results: The convalescence phase of moderate COVID-19 was associated with a decrease in sIgA levels in nasal swabs, persistently high sIgA levels in salivary gland secretions and no changes in pharyngeal swabs with the levels similar to those in healthy subjects. The addition of an immuno-stimulant agent to combination therapy for patients with COVID-19 stimulates the production of sIgA in the nasal and pharyngeal compartments, reduces C-reactive protein (CRP) levels and shortens the duration of fever and the length of hospital stay. Conclusion: Using an immuno-modulatory agent containing bacterial ligands in therapy for COVID-19 patients enhances the production of sIgA in the nasal and pharyngeal compartments and improves the course of the disease.
Authors and Affiliations
Michail Kostinov, Oksana Svitich1 Alexander Chuchalin Valerij Osipcov Ekaterina Khromova Natal’ya Abramova Vitalij Tatevosov Anna Vlasenko Viliya Gajnitdinova Dmitry Pakhomov Kirill Mashilov Tat’yana Ospel’nikova Natal’ya Mikhailova Valentina Polishchuk Ekaterina Kurbatova1 Aristitsa Kostinova
Keywords
Related Articles
- EP ID EP741777
- DOI 10.35248/2155-9899.23.14.682
- Views 15
- Downloads 0
Hotairm1 Controls S100A9 Protein Phosphorylation in Myeloid-Derived Suppressor Cells during Sepsis
During the acute phase of sepsis, the S100A9 proinflammatory protein resides in the cytosol in a phosphorylated form. In contrast, S100A9 relocalizes to the nucleus in an unphosphorylated form during the late/chronic sep...
Secretory IgA and Course of COVID-19 in Patients Receiving a BacteriaBased Immunostimulant Agent in Addition to Background Therapy
Background: Mucosal immunity plays a major role not only in the prevention but probably also in the outcome of COVID-19. An enhanced production of secretory Immunoglobulin A (sIgA) might contribute to the activation of t...
Exercise-Mediated Immune Protection in Chronic Kidney Disease Decreases Infection and Severe Evolution of COVID-19
It is constantly sought to understand the different mechanisms of action of the immune system to establish potential efficient therapeutic targets for different clinical situations. Thus, the present study aims to expand...
Measurement of Post Challenging Immune Response (Serum?s Th1, Th2 Cytokines and Spleen?s CD Markers) with L.Major Amastigote in Balb/c Mice
Introduction: Leishmaniasis is a disease caused by the Leishmania major parasites and afflicted a large number of people every year. This disease is immunologically complex and in some cases, spontaneous improvement is a...
Indoleamine 2,3-Dioxygenase (IDO); Silenced Dendritic Cell Vaccine with Ipilimumab in Treating Metastatic Melanoma Patients: A Case Report
Immunotherapy has revolutionized the treatment landscape for metastatic melanoma. This case report presents the clinical course of a patient with metastatic melanoma who received combination therapy with ipilimumab, a CT...